US6171609B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic inhibitor of vascular smooth muscle cells
Assignee: UAB Research Foundation
•
Filing: 1995-10-23
•
Granted: 2001-01-09
•
Expires: 2015-10-23
Abstract
Abstract Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
Inventors
- 👤 Lawrence L. Kunz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:17
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/04; A61K31/13; A61K31/131; A61K31/135; A61K31/138; A61K31/16; A61K31/165; A61K31/17; A61K31/33; A61K31/335; A61K31/337; A61K31/365; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K31/495; A61K31/505; A61K31/519; A61K31/55; A61K31/551; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/69; A61K47/6921; A61K47/6923; A61K47/6927; A61K47/6957; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61L; A61L31/00; A61L31/14; A61L31/148; A61L31/16; A61P; A61P35/00; A61P41/00; A61P43/00; A61P7/00; A61P9/00; A61P9/08; A61P9/10; B; B82; B82Y; B82Y5/00; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602; A61L2300/604; A61L2300/606; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/775; Y10S977/788; Y10S977/802; Y10S977/806; Y10S977/808; Y10S977/902; Y10S977/904; Y10S977/905; Y10S977/906; Y10S977/915; Y10S977/916
Claims Analysis
Total Claims: 78
Claim 1
Independent Claim
22 words
An intravascular stent comprising an amount of a cytoskeletal inhibitor effective to inhibit stenosis or reduce restenosis following placement of the stent.
Claim 2
Dependent Claim
22 words
An intravascular stent comprising an amount of a cytoskeletal inhibitor effective to inhibit stenosis or reduce restenosis following placement of the stent.
Claim 3
Dependent Claim
17 words
The intravascular stent of claim 1 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 4
Dependent Claim
16 words
The intravascular stent of claim 1 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 5
Dependent Claim
11 words
The intravascular stent of claim 1 which comprises metal or plastic.
Claim 6
Dependent Claim
11 words
The intravascular stent of claim 1 which comprises a biodegradable material.
Claim 7
Dependent Claim
13 words
The intravascular stent of claim 4 which consists essentially of a biodegradable material.
Claim 8
Dependent Claim
16 words
The intravascular stent of claim 1 which comprises the cytoskeletal inhibitor in a sustained release form.
Claim 9
Dependent Claim
17 words
The intravascular stent of claim 7 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 10
Dependent Claim
16 words
The intravascular stent of claim 7 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 11
Dependent Claim
38 words
The intravascular stent of claim 7 wherein the sustained release form of the cytoskeletal inhibitor comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 12
Dependent Claim
22 words
The intravascular stent of claim 1 wherein the stent comprises a biodegradable coating or a porous non-biodegradable coating comprising the cytoskeletal inhibitor.
Claim 13
Dependent Claim
16 words
The intravascular stent of claim 1 which further comprises an inhibitor of smooth muscle cell proliferation.
Claim 14
Dependent Claim
11 words
The intravascular stent of claim 11 herein the coating is biodegradable.
Claim 15
Dependent Claim
11 words
The intravascular stent of claim 11 herein the coating is porous.
Claim 16
Dependent Claim
19 words
The intravascular stent of claim 11 wherein the coating comprises a sustained release dosage form of the cytoskeletal inhibitor.
Claim 17
Dependent Claim
17 words
The intravascular stent of claim 15 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 18
Dependent Claim
16 words
The intravascular stent of claim 15 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 19
Dependent Claim
42 words
An intravascular stent comprising an amount of a cytostatic therapeutic agent which does not exhibit substantial cytotoxicity, which agent is effective to inhibit stenosis or reduce restenosis following placement of the stent, wherein the therapeutic agent is not heparin or a radioisotope.
Claim 20
Dependent Claim
42 words
An intravascular stent comprising an amount of a cytostatic therapeutic agent which does not exhibit substantial cytotoxicity, which agent is effective to inhibit stenosis or reduce restenosis following placement of the stent, wherein the therapeutic agent is not heparin or a radioisotope.
Claim 21
Dependent Claim
14 words
The intravascular stent of claim 18 wherein the stent further comprises a cytoskeletal inhibitor.
Claim 22
Dependent Claim
17 words
The intravascular stent of claim 19 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 23
Dependent Claim
16 words
The intravascular stent of claim 19 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 24
Dependent Claim
16 words
The intravascular stent of claim 19 which comprises the cytoskeletal inhibitor in a sustained release form.
Claim 25
Dependent Claim
17 words
The intravascular stent of claim 22 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 26
Dependent Claim
16 words
The intravascular stent of claim 22 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 27
Dependent Claim
37 words
The intravascular stent of claim 22 wherein the sustained release form of the cytoskeletal inhibitor comprises a binding peptide or protein which specifically binds to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 28
Dependent Claim
22 words
The intravascular stent of claim 19 wherein the stent comprises a biodegradable coating or a porous non-biodegradable coating comprising the cytoskeletal inhibitor.
Claim 29
Dependent Claim
11 words
The intravascular stent of claim 26 wherein the coating is biodegradable.
Claim 30
Dependent Claim
11 words
The intravascular stent of claim 26 wherein the coating is porous.
Claim 31
Dependent Claim
19 words
The intravascular stent of claim 26 wherein the coating comprises a sustained release dosage form of the cytoskeletal inhibitor.
Claim 32
Dependent Claim
17 words
The intravascular stent of claim 29 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 33
Dependent Claim
16 words
The intravascular stent of claim 29 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 34
Dependent Claim
11 words
The intravascular stent of claim 18 which comprises metal or plastic.
Claim 35
Dependent Claim
11 words
The intravascular stent of claim 18 which comprises a biodegradable material.
Claim 36
Dependent Claim
13 words
The intravascular stent of claim 33 which consists essentially of a biodegradable material.
Claim 37
Dependent Claim
26 words
The intravascular stent of claim 2 , 8 , 16 , 20 , 23 or 30 wherein the cytochalasin is cytochalasin B or an analog thereof.
Claim 38
Dependent Claim
39 words
An intravascular stent comprising a matrix and a coating on said matrix, wherein the coating and the matrix together comprise an amount of a cytoskeletal inhibitor effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent.
Claim 39
Dependent Claim
39 words
An intravascular stent comprising a matrix and a coating on said matrix, wherein the coating and the matrix together comprise an amount of a cytoskeletal inhibitor effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent.
Claim 40
Dependent Claim
16 words
The intravascular stent of claim 36 wherein the coating comprises a cytochalasin or an analog thereof.
Claim 41
Dependent Claim
15 words
The intravascular stent of claim 36 wherein the coating comprises taxol or an analog thereof.
Claim 42
Dependent Claim
18 words
The intravascular stent of claim 36 wherein the matrix is impregnated with a cytochalasin or an analog thereof.
Claim 43
Dependent Claim
17 words
The intravascular stent of claim 36 wherein the matrix is impregnated with taxol or an analog thereof.
Claim 44
Dependent Claim
14 words
The intravascular stent of claim 37 or 39 wherein the cytochalasin comprises cytochalasin B.
Claim 45
Dependent Claim
21 words
The intravascular stent of claim 37 or 39 wherein the cytochalasin or an analog thereof is in sustained release dosage form.
Claim 46
Dependent Claim
20 words
The intravascular stent of claim 38 or 36 wherein taxol or an analog thereof is in sustained release dosage form.
Claim 47
Dependent Claim
26 words
An intravascular stent comprising an amount of a cytochalasin or an analog thereof effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent.
Claim 48
Dependent Claim
26 words
An intravascular stent comprising an amount of a cytochalasin or an analog thereof effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent.
Claim 49
Dependent Claim
21 words
The intravascular stent of claim 44 wherein the matrix of the stent is impregnated with the cytochalasin or an analog thereof.
Claim 50
Dependent Claim
17 words
The intravascular stent of claim 44 which comprises a coating comprising the cytochalasin or an analog thereof.
Claim 51
Dependent Claim
14 words
The intravascular stent of claim 45 or 46 wherein the cytochalasin comprises cytochalasin B.
Claim 52
Dependent Claim
21 words
The intravascular stent of claim 45 or 46 wherein the cytochalasin or an analog thereof is in sustained release dosage form.
Claim 53
Dependent Claim
22 words
The intravascular stent of claim 46 wherein the matrix is impregnated with an amount of an inhibitor of smooth muscle cell proliferation.
Claim 54
Dependent Claim
23 words
The intravascular stent of claim 45 which further comprises a coating comprising a cytostatic amount of an inhibitor of smooth muscle cell proliferation.
Claim 55
Dependent Claim
17 words
The intravascular stent of claim 46 wherein the matrix is impregnated with taxol or an analog thereof.
Claim 56
Dependent Claim
17 words
The intravascular stent of claim 45 which further comprises a coating comprising taxol or an analog thereof.
Claim 57
Dependent Claim
22 words
The intravascular stent of claim 49 or 50 wherein the inhibitor of smooth muscle cell proliferation is in sustained release dosage form.
Claim 58
Dependent Claim
20 words
The intravascular stent of claim 51 or 52 wherein the taxol or analog thereof is in sustained release dosage form.
Claim 59
Dependent Claim
37 words
An intravascular stent comprising a cytostatic amount of an inhibitor of smooth muscle cell proliferation effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent, wherein the inhibitor is in sustained release dosage form.
Claim 60
Dependent Claim
37 words
An intravascular stent comprising a cytostatic amount of an inhibitor of smooth muscle cell proliferation effective to inhibit stenosis or reduce restenosis following placement of the therapeutic stent, wherein the inhibitor is in sustained release dosage form.
Claim 61
Dependent Claim
19 words
The intravascular stent of claim 55 wherein the matrix is impregnated with the inhibitor of smooth muscle cell proliferation.
Claim 62
Dependent Claim
15 words
The intravascular stent of claim 56 which further comprises a coating comprising a cytoskeletal inhibitor.
Claim 63
Dependent Claim
18 words
The intravascular stent of claim 55 which comprises a coating comprising the inhibitor of smooth muscle cell proliferation.
Claim 64
Dependent Claim
15 words
The intravascular stent of claim 58 wherein the matrix is impregnated with a cytoskeletal inhibitor.
Claim 65
Dependent Claim
19 words
The intravascular stent of claim 57 or 59 wherein the cytoskeletal inhibitor comprises a cytochalasin or an analog thereof.
Claim 66
Dependent Claim
12 words
The intravascular stent of claim 60 wherein the cytochalasin comprises cytochalasin B.
Claim 67
Dependent Claim
18 words
The intravascular stent of claim 57 or 59 wherein the cytoskeletal inhibitor comprises taxol or an analog thereof.
Claim 68
Dependent Claim
18 words
The intravascular stent of claim 57 or 59 wherein the cytoskeletal inhibitor is in sustained release dosage form.
Claim 69
Dependent Claim
25 words
The intravascular stent of claim 36 , 46 , 50 , 52 , 57 or 58 wherein the coating is formed from a biodegradable material.
Claim 70
Dependent Claim
22 words
The intravascular stent of claim 36 , 44 or 55 wherein the stent is formed from a porous or permeable non-biodegradable material.
Claim 71
Dependent Claim
19 words
The intravascular stent of claim 36 , 44 or 55 in which the intravascular stent comprises metal or plastic.
Claim 72
Dependent Claim
19 words
The intravascular stent of claim 36 , 44 or 55 wherein the stent is formed from a biodegradable material.
Claim 73
Dependent Claim
34 words
The intravascular stent of claim 53 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 74
Dependent Claim
34 words
The intravascular stent of claim 42 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 75
Dependent Claim
34 words
The intravascular stent of claim 43 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 76
Dependent Claim
34 words
The intravascular stent of claim 48 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 77
Dependent Claim
34 words
The intravascular stent of claim 54 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
Claim 78
Dependent Claim
34 words
The intravascular stent of claim 63 wherein the sustained release form comprises a binding peptide or protein capable of specifically binding to smooth muscle cells, stromal cells or interstitial matrix surrounding smooth muscle cells.
References Cited (Backward Citations)
US4093709A
Cited
US4675189A
Cited
US4485096A
Cited
US4485097A
Cited
US4555402A
Cited
US4867973A
Cited
US4897255A
Cited
US4962091A
Cited
US4879225A
Cited
US5093330A
Cited
EP0297946A2
Cited
WO1988010259A1
Cited
US5527337A
Cited
US5216024A
Cited
US4929602A
Cited
US5468746A
Cited
US5213580A
Cited
US5208019A
Cited
US5066789A
Cited
US5268358A
Cited
US5380716A
Cited
US5073633A
Cited
US5026537A
Cited
WO1990013293A1
Cited
US5288735A
Cited
US5248764A
Cited
US5346897A
Cited
US5395610A
Cited
US5208238A
Cited
US5364843A
Cited
US5112305A
Cited
US5043335A
Cited
EP0411893A2
Cited
US5176617A
Cited
US5059166A
Cited
US5049132A
Cited
US5199939B1
Cited
US5199939A
Cited
US5328471A
Cited
US5260224A
Cited
US5180366A
Cited
US5053033A
Cited
US5308622A
Cited
US5102402A
Cited
US5171217A
Cited
US5116864A
Cited
WO1992021363A1
Cited
US5213576A
Cited
US5185260A
Cited
WO1993009790A1
Cited
US5238950A
Cited
US5326757A
Cited
US5516781A
Cited
EP0622076A1
Cited
US5423885A
Cited
WO1993024476A1
Cited
US5344926A
Cited
US5283257A
Cited
WO1994003644A1
Cited
WO1994004178A1
Cited
US5460807A
Cited
EP0588518A1
Cited
US5385935A
Cited
WO1994007529A1
Cited
US5354774A
Cited
WO1994015646A1
Cited
WO1994016706A1
Cited
WO1994018345A1
Cited
WO1994018968A1
Cited
US5358844A
Cited
WO1994018967A1
Cited
US5453436A
Cited
WO1994020096A1
Cited
US5308862A
Cited
WO1994020097A1
Cited
WO1994021679A1
Cited
WO1994022436A1
Cited
WO1994025053A1
Cited
US5342926A
Cited
US5407658A
Cited
WO1994028721A1
Cited
WO1995003036A1
Cited
WO1995003795A1
Cited
US5441947A
Cited
US5429634A
Cited
US5324739A
Cited
US5393772A
Cited
US5519042A
Cited
US5583153A
Cited
US5516807A
Cited
US5498775A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-01-09 | 2004-07-10 | 2005-01-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-01-09 | 2008-07-10 | 2009-01-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-01-09 | 2012-07-10 | 2013-01-09 | $7700.00 | Window Closed / Lapsed |